Topiramate in patients with epilepsy and intellectual disability

被引：14

作者：

Martin, Peter ^{[1
]}

Schreiner, Andreas ^{[2
]}

Rettig, Klaus ^{[3
]}

Schaeuble, Barbara ^{[2
]}

机构：

[1] Epilepsy Ctr Kork, Seguin Clin Persons Severe Intellectual Disabil, Kehl, Germany

[2] Janssen Cilag GmbH, Neuss, Germany

[3] Gesell Evaluat & Qualitatssicherung Med, GEM, Meerbusch, Germany

来源：

EPILEPSY & BEHAVIOR | 2009年 / 14卷 / 03期

关键词：

Topiramate; Epilepsy; Intellectual disability; Seizure; Behavior; Aberrant Behavior Checklist (ABC); Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER) scale; SEVERE RETARDATION MESSIER; LENNOX-GASTAUT-SYNDROME; MATSON EVALUATION; SOCIAL-SKILLS; CONTROLLED-TRIAL; ADVERSE EVENTS; WEST-SYNDROME; INDIVIDUALS; CHILDREN; ADULTS;

D O I：

10.1016/j.yebeh.2008.12.017

中图分类号：

B84 [心理学]; C [社会科学总论]; Q98 [人类学];

学科分类号：

03 ; 0303 ; 030303 ; 04 ; 0402 ;

摘要：

This noninterventional single-arm study explored effectiveness and behavioral outcomes in intellectually disabled patients treated with topiramate for epilepsy. Data from 21 patients diagnosed with cerebral palsy were available for evaluation. Behavioral changes were assessed using the validated Aberrant Behavior Checklist and Matson Evaluation of Social Skills for individuals with Severe Retardation (MESSIER) scales. Some improvement in nearly all behavioral aspects was observed under concomitant topiramate therapy; for example, the Aberrant Behavior Checklist total score changed from 33.7 +/- 25.8 to 25.3 +/- 19.1 (P = 0.047). In addition, seizure frequency decreased from 16.1 +/- 22.2/4 weeks to 12.2 +/- 17.0/4 weeks (N = 2 1, P = 0.164). Fifty-two percent of the patients experienced at least 50% seizure reduction during the 24-week treatment period. The safety profile is in accordance with the current Summary of Product Characteristics of Topiramate. Two unexpected deaths were attributed to sudden unexpected death in epilepsy. (C) 2009 Elsevier Inc. All rights reserved.

引用

页码：496 / 502

页数：7

共 26 条

[1] Topiramate in long-term treatment of epilepsy in the intellectually disabled [J].

Arvio, M ;

Sillanpää, M .

JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2005, 49 :183-189

[2]

Besag Frank M C, 2004, Expert Opin Drug Saf, V3, P1

[3] Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study [J].

Coppola, G ;

Caliendo, G ;

Veggiotti, P ;

Romeo, A ;

Tortorella, G ;

De Marco, P ;

Pascotto, A .

EPILEPSY RESEARCH, 2002, 51 (1-2) :147-153

[4] A pilot study of topiramate in the treatment of infantile spasms [J].

Glauser, TA ;

Clark, PO ;

Strawsburg, R .

EPILEPSIA, 1998, 39 (12) :1324-1328

[5]

Glauser TA, 2000, EPILEPSIA, V41, pS91

[6]

Glauser TA, 2000, EPILEPSIA, V41, pS86

[7] A pilot study of topiramate in children with Lennox- Gastaut syndrome [J].

Guerreiro, MM ;

Manreza, MLG ;

Scotoni, AE ;

Silva, EA ;

Guerreiro, CAM ;

Souza, EAP ;

Ferreira, VB ;

Reed, UC ;

Diament, A ;

Trefiglio, R ;

Chiu, HC ;

Bacaltchuk, J .

ARQUIVOS DE NEURO-PSIQUIATRIA, 1999, 57 (2A) :167-175

[8] Topiramate-induced psychosis in two members of the one family: A case report [J].

José R.J.P. ;

Cairns A. ;

Babbs C. .

Journal of Medical Case Reports, 2 (1)

[9] A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events [J].

Kanner, AM ;

Wuu, J ;

Faught, E ;

Tatum, WO ;

Fix, A ;

French, JA .

EPILEPSY & BEHAVIOR, 2003, 4 (05) :548-552

[10] A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: Impact on seizures, severity, and quality of life [J].

Kerr, MP ;

Baker, GA ;

Brodie, MJ .

EPILEPSY & BEHAVIOR, 2005, 7 (03) :472-480

← 1 2 3 →